This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Epizyme Crescita futura
Future criteri di controllo 2/6
Informazioni chiave
15.8%
Tasso di crescita degli utili
16.6%
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 28.0% |
Tasso di crescita dei ricavi | 37.6% |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | Low |
Ultimo aggiornamento | n/a |
Aggiornamenti recenti sulla crescita futura
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2024 | 136 | -173 | N/A | N/A | 3 |
12/31/2023 | 80 | -196 | N/A | N/A | 4 |
12/31/2022 | 49 | -182 | N/A | N/A | 4 |
6/30/2022 | 53 | -208 | -209 | -209 | N/A |
3/31/2022 | 38 | -236 | -211 | -210 | N/A |
12/31/2021 | 37 | -251 | -227 | -227 | N/A |
9/30/2021 | 34 | -267 | -229 | -228 | N/A |
6/30/2021 | 33 | -257 | -229 | -228 | N/A |
3/31/2021 | 22 | -251 | -250 | -224 | N/A |
12/31/2020 | 16 | -232 | -257 | -206 | N/A |
9/30/2020 | 12 | -222 | -239 | -189 | N/A |
6/30/2020 | 14 | -202 | -235 | -184 | N/A |
3/31/2020 | 17 | -192 | -200 | -174 | N/A |
12/31/2019 | 24 | -173 | -148 | -147 | N/A |
9/30/2019 | 29 | -140 | -135 | -134 | N/A |
6/30/2019 | 23 | -141 | -132 | -132 | N/A |
3/31/2019 | 30 | -122 | -123 | -123 | N/A |
12/31/2018 | 22 | -124 | -122 | -122 | N/A |
9/30/2018 | 12 | -137 | -130 | -129 | N/A |
6/30/2018 | 12 | -137 | -133 | -133 | N/A |
3/31/2018 | 10 | -136 | -119 | -118 | N/A |
12/31/2017 | 10 | -134 | -121 | -120 | N/A |
9/30/2017 | 10 | -133 | -112 | -111 | N/A |
6/30/2017 | 17 | -120 | -98 | -97 | N/A |
3/31/2017 | 8 | -120 | -105 | -104 | N/A |
12/31/2016 | 8 | -110 | -97 | -96 | N/A |
9/30/2016 | 8 | -97 | -97 | -97 | N/A |
6/30/2016 | 2 | -96 | -80 | -79 | N/A |
3/31/2016 | 2 | -94 | N/A | -76 | N/A |
12/31/2015 | 3 | -132 | N/A | -73 | N/A |
9/30/2015 | 12 | -125 | N/A | -72 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: EPZM is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: EPZM is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: EPZM is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: EPZM's revenue (37.6% per year) is forecast to grow faster than the US market (7.9% per year).
Ricavi ad alta crescita: EPZM's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if EPZM's Return on Equity is forecast to be high in 3 years time